세계의 의약품 건조 장비 시장 : 유형별, 운영 규모별, 최종 사용자별, 지역별 - 예측(-2029년)

The global Pharmaceutical Drying Equipment market is projected to reach USD 8.18 billion by 2029 from USD 5.80 billion in 2024, at a CAGR of 7.1% during the forecast period. This is due to growing prevalence of chronic diseases such as diabetes, cardiovascular diseases, cancer, is leading to increase in demand for the pharmaceutical drugs. To meet this increased demand for the medicines the pharmaceutical manufacturing facilities are expanding, consequently increasing the demand for the pharmaceutical equipment dryers. However, the increased demand for the refurbished dryers in pharmaceutical industry is major restraint to the market. Additionally, Higher maintenance of the pharmaceutical drying equipment is major challenge for the market growth. But, the increasing competition in pharmaceutical manufacturing industry due to loss of various drugs' market exclusivity and high growth potential of emerging markets is expected to present profitable growth opportunities for pharmaceutical drying equipment market players over the forecast period of 2024-2029.

"The spray dryer segment of pharmaceutical drying market to hold largest position forecast period."

Based on the type, the spray dryer segment is anticipated to hold largest share position during forecast period in pharmaceutical drying equipment market. This is due to its versatility, efficiency, and ability to enhance product quality. It offers improved bioavailability by producing dust-free, free-flowing, and easily re-dispersible powders, making it ideal for thermoplastic, hygroscopic, and heat-sensitive products. Spray dryers are essential for maintaining quality of active pharmaceutical ingredient. As spray dryers can handle a wide variety of product types, including granulated and agglomerated forms, without heat deterioration. Its popularity in the sector is also a result of its small size, which guarantees energy-efficient operations and makes it an affordable option for large-scale pharmaceutical production.

"The pilot-scale equipment segment is the fastest growing segment in pharmaceutical drying equipment market."

Based on scale of operation, the pharmaceutical drying equipment market is segmented into industrial-scale equipment, pilot-scale equipment, and laboratory-scale equipment. The pilot-scale equipment segment is expected to grow at the highest CAGR due to its pivotal role in pharmaceutical research and development (R&D). With increasing development of new medications, pilot-scale equipment allows manufacturers to test formulations and processes on a smaller, more cost-effective scale before full-scale industrial production. This affordability makes it an ideal choice during R&D, minimizing financial risk while optimizing production methods. Additionally, the growing trend of outsourcing manufacturing to Contract Development and Manufacturing Organizations (CDMOs) has further driven the demand for pilot-scale equipment. CDMOs use these systems to streamline the transition from R&D to large-scale production, ensuring efficient and scalable solutions for pharmaceutical companies. As more companies rely on CDMOs to bring new drugs to market, the need for pilot-scale equipment continues to rise, contributing to its rapid growth.

"Europe accounted for the second largest share of the pharmaceutical drying equipment market by region."

The global pharmaceutical drying equipment market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is the second largest regional market for pharmaceutical drying equipment, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

Europe holds the second-largest position in the pharmaceutical drying equipment market. This is due to the presence of key industry players such as GEA Group (Germany), I.M.A. Industria Macchine Automatiche (Italy), Syntegon Technology GmbH (Germany), and Mechatech Systems Ltd (UK). These major European players are making significant investments in R&D to create cutting-edge, innovative equipment. Furthermore, the European region's strong pharmaceutical manufacturing base, established regulatory framework, and focus on technological advancements all contribute to its strong market position. In Europe, the need for pharmaceutical drying equipment is being driven by innovation and industry leadership.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
• By Designation: C-level-50%, Director-level-30% and Others-20%
• By Region: North America-38%, Europe-26%, Asia Pacific-15%, Latin America- 11%, and Middle East and Africa-10%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = > USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the pharmaceutical drying equipment market are GEA Group (Germany), ATS Corporation (US), Hosokawa Micron Group (Japan), Freund Corporation (Japan), I.M.A. Industria Macchine Automatiche S.p.A. (Italy), Syntegon Technology GmbH (Germany), BUCHI Labortechnik AG (Switzerland), OPTIMA packaging group GmbH (Germany), Mechatech Systems Ltd (Netherland), and BEW Engineering Limited (India).

Research Coverage

This report studies the pharmaceutical drying equipment market based on type, scale of operation,, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (The expansion of pharmaceutical manufacturing facilities to drive market growth, The increased demand for biopharmaceuticals to drive market, The rapid growth of the contact manufacturing companies to drive market), restraints (The demand for refurbished drying equipment is restraining the market) , Challenge (Higher maintenance of the pharmaceutical drying equipment is major challenge for the market), opportunity (Increasing competition in pharmaceutical manufacturing industry due to loss of various drugs' market exclusivity, High growth potential of emerging markets)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pain management devices market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drying equipment market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS AND REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key objectives of secondary research
    • 2.1.1.2 Key secondary sources
    • 2.1.1.3 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.2.2 TOP-DOWN APPROACH
  • 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 DEMAND-SIDE ANALYSIS (USING PHARMACEUTICAL DRYING EQUIPMENT ADOPTION)
• 2.3 DATA TRIANGULATION
• 2.4 MARKET RANKING ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PHARMACEUTICAL DRYING EQUIPMENT MARKET OVERVIEW
• 4.2 NORTH AMERICA: PHARMACEUTICAL DRYING EQUIPMENT MARKET, BY END USER, 2023
• 4.3 GEOGRAPHIC SNAPSHOT OF PHARMACEUTICAL DRYING EQUIPMENT MARKET, 2024-2029
• 4.4 PHARMACEUTICAL DRYING EQUIPMENT MARKET: REGIONAL MIX, 2022-2029
• 4.5 PHARMACEUTICAL DRYING EQUIPMENT MARKET: DEVELOPED VS. EMERGING MARKETS, 2024 VS. 2029 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expansion of pharmaceutical manufacturing facilities
    • 5.2.1.2 High demand for biopharmaceuticals
    • 5.2.1.3 Rapid growth of contract manufacturing and development companies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Increased demand for refurbished drying equipment
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increased market competition and high demand for generic and biosimilar drugs
    • 5.2.3.2 High growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Need for regular maintenance and high associated costs
• 5.3 INDUSTRY TRENDS
  • 5.3.1 AUTOMATION AND DIGITALIZATION
  • 5.3.2 ENVIRONMENTAL SUSTAINABILITY
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Automation and control systems
    • 5.4.1.2 Heat transfer technology
    • 5.4.1.3 Vacuum technology
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 High-efficiency particulate air (HEPA) filtration technology
    • 5.4.2.2 Temperature control systems
    • 5.4.2.3 Desorption technology
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Moisture sensors and monitoring systems
    • 5.4.3.2 Air distribution systems
    • 5.4.3.3 Particle size analysis technology
• 5.5 PORTER'S FIVE FORCE ANALYSIS
  • 5.5.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.5.2 BARGAINING POWER OF SUPPLIERS
  • 5.5.3 BARGAINING POWER OF BUYERS
  • 5.5.4 THREAT OF SUBSTITUTES
  • 5.5.5 THREAT OF NEW ENTRANTS
• 5.6 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.6.2 KEY BUYING CRITERIA
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 REGULATORY ANALYSIS
    • 5.7.1.1 North America
      • 5.7.1.1.1 US
      • 5.7.1.1.2 Canada
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Latin America
    • 5.7.1.5 Middle East & Africa
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS IN PHARMACEUTICAL DRYING EQUIPMENT MARKET
  • 5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TRADE ANALYSIS
  • 5.9.1 IMPORT DATA FOR HS CODE 8419
  • 5.9.2 EXPORT DATA FOR HS CODE 8419
• 5.10 PRICING ANALYSIS
  • 5.10.1 INDICATIVE SELLING PRICE OF DRYERS, BY PRODUCT
  • 5.10.2 INDICATIVE SELLING PRICE OF DRYERS, BY REGION
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 UNMET NEEDS
• 5.13 END-USER EXPECTATIONS
• 5.14 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRYING EQUIPMENT MARKET
  • 5.14.1 KEY USE CASES
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: IMPROVED VACUUM PRESSURE TO REDUCE DRYING TIME, INCREASE QUALITY, AND SAVE PRODUCTION COSTS
  • 5.16.2 CASE STUDY 2: OPTIMIZED PARTICLE SIZE DISTRIBUTION FOR HIGH-POTENCY API PRODUCTION
  • 5.16.3 CASE STUDY 3: INNOVATIVE CONTAINMENT SOLUTIONS FOR HIGH-POTENCY APIS TO ENHANCE NUTSCHE FILTER DRYER PERFORMANCE
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 ADJACENT MARKET ANALYSIS
  • 5.18.1 SPRAY DRYING EQUIPMENT MARKET
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.20 INVESTMENT AND FUNDING SCENARIO

6 PHARMACEUTICAL DRYING EQUIPMENT MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 SPRAY DRYERS
  • 6.2.1 ABILITY TO MAINTAIN STABILITY OF THERMALLY SENSITIVE COMPOUNDS THROUGH RAPID DRYING TO PRESERVE DRUG EFFICACY
• 6.3 FREEZE DRYERS
  • 6.3.1 RISING DEMAND FOR LYOPHILIZED PRODUCTS TO DRIVE MARKET
• 6.4 FLUIDIZED BED DRYERS
  • 6.4.1 COST-EFFECTIVENESS AND UNIFORM DRYING TO SPUR DEMAND IN PHARMACEUTICAL MANUFACTURING FACILITIES
• 6.5 VACUUM DRYERS
  • 6.5.1 VACUUM DRYERS TO MINIMIZE THERMAL DEGRADATION AND PROVIDE STABILITY TO HEAT-SENSITIVE MATERIALS
• 6.6 OTHER DRYERS

7 PHARMACEUTICAL DRYING EQUIPMENT MARKET, BY SCALE OF OPERATION

• 7.1 INTRODUCTION
• 7.2 INDUSTRIAL-SCALE EQUIPMENT
  • 7.2.1 RISING INVESTMENTS IN HIGH-QUALITY MANUFACTURING TO AUGMENT MARKET GROWTH
• 7.3 PILOT-SCALE EQUIPMENT
  • 7.3.1 INCREASED PHARMACEUTICAL R&D INVESTMENTS AND FOCUS ON EFFECTIVE QUALITY CONTROL IN LARGER OPERATIONS TO DRIVE MARKET
• 7.4 LABORATORY-SCALE EQUIPMENT
  • 7.4.1 COST-EFFECTIVENESS, EASY OPERATION, AND LOW MAINTENANCE NEEDS TO FUEL MARKET GROWTH

8 PHARMACEUTICAL DRYING EQUIPMENT MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL AND BIOTECH COMPANIES
  • 8.2.1 INCREASED INVESTMENTS FOR BETTER PRODUCTION EFFICIENCY IN PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
• 8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
  • 8.3.1 INCREASED OUTSOURCING OF RESEARCH AND MANUFACTURING PROCESSES BY PHARMA COMPANIES TO PROPEL MARKET GROWTH
• 8.4 RESEARCH ACADEMIES AND UNIVERSITIES
  • 8.4.1 RISING DEMAND FOR ADVANCED LABORATORY AND RESEARCH FACILITIES IN ACADEMIC SETTINGS TO DRIVE MARKET

9 PHARMACEUTICAL DRYING EQUIPMENT MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American pharmaceutical drying equipment market during forecast period
  • 9.2.3 CANADA
    • 9.2.3.1 Robust pharmaceutical sector and advancements in drug development to aid market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Increased R&D investments by key players and technological advancements to support market growth
  • 9.3.3 FRANCE
    • 9.3.3.1 Rising investments in bioproduction capacities to spur market growth
  • 9.3.4 ITALY
    • 9.3.4.1 Growing demand for biologics and biopharmaceuticals to boost market growth
  • 9.3.5 UK
    • 9.3.5.1 Increased government investments in pharmaceuticals and clinical trials to propel market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Increasing collaborations between drying equipment manufacturing companies to aid market growth
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Technological advancements and strategic expansions by key international players to augment market growth
  • 9.4.3 JAPAN
    • 9.4.3.1 High investments in manufacturing capabilities and increased geriatric population to aid market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Increasing investments in manufacturing facilities to propel market growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Rising demand for pharmaceuticals and increasing advancements in drug formulations to drive market
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Increased popularity of CDMOs for pharmaceutical production to fuel market growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Advanced biologics sector and increased demand for biosimilars to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Burgeoning pharmaceutical industry and favorable trade agreements to propel market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Expansion of pharmaceutical manufacturing companies to drive market
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRYING EQUIPMENT MARKET
• 10.3 REVENUE ANALYSIS, 2021-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Type footprint
    • 10.5.5.3 Scale of operation footprint
    • 10.5.5.4 End-user footprint
    • 10.5.5.5 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 GEA GROUP AKTIENGESELLSCHAFT
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 IMA INDUSTRIA MACCHINE AUTOMATICHE SPA
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 MnM view
      • 11.1.2.3.1 Right to win
      • 11.1.2.3.2 Strategic choices
      • 11.1.2.3.3 Weaknesses and competitive threats
  • 11.1.3 ATS CORPORATION
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches
      • 11.1.3.3.2 Deals
      • 11.1.3.3.3 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 HOSOKAWA MICRON GROUP
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 MnM view
      • 11.1.4.3.1 Right to win
      • 11.1.4.3.2 Strategic choices
      • 11.1.4.3.3 Weaknesses and competitive threats
  • 11.1.5 FREUND CORP.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
  • 11.1.6 SYNTEGON TECHNOLOGY GMBH
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
  • 11.1.7 BUCHI LABORTECHNIK AG
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches
  • 11.1.8 OPTIMA
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
  • 11.1.9 MECHATECH SYSTEMS LTD.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 BEW ENGINEERING
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 ZIRBUS TECHNOLOGY GMBH
  • 11.2.2 SPX FLOW, INC.
  • 11.2.3 EUROPEAN SPRAYDRY TECHNOLOGIES
  • 11.2.4 YAMATO SCIENTIFIC CO., LTD.
  • 11.2.5 SAKA
  • 11.2.6 ILSHIN BIOBASE
  • 11.2.7 OKAWARA MFG. CO., LTD.
  • 11.2.8 CHANGZHOU CHANGJIANG DRYING EQUIPMENT CO., LTD.
  • 11.2.9 BACHILLER
  • 11.2.10 MILLROCK TECHNOLOGY, INC.
  • 11.2.11 MARTIN CHRIST GEFRIERTROCKNUNGSANLAGEN GMBH
  • 11.2.12 LABCONCO
  • 11.2.13 O'HARA TECHNOLOGIES
  • 11.2.14 COOLVACUUM TECHNOLOGIES, SL
  • 11.2.15 SHACHI ENGINEERING PVT. LTD.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS